Every Form 4 that Compass Therapeutics, Inc. (CMPX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CMPX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPX filings page.
Compass Therapeutics, Inc. (CMPX) Chief Accounting Officer Neil Lerner purchased 20,000 shares of common stock at $0.92 per share on October 1, 2026. The purchase was reported as direct; no Rule 10b5-1 plan is reported. Lerner’s reported holdings after the purchase were 420,000 shares, including 62,500 unvested restricted stock units subject to service-based vesting in four equal annual installments, with the first installment vesting on January 2, 2027.
Neil Lerner, Compass Therapeutics, Inc.’s Chief Accounting Officer, reported a direct purchase of 2,500 common shares at $1.14 per share on September 24, 2026. His reported direct position after the purchase was 400,000 shares, including 62,500 unvested restricted stock units. No Rule 10b5-1 plan is reported.
Compass Therapeutics, Inc. Chief Accounting Officer Neil Lerner reported an open-market purchase of common stock. On April 29, 2026, he bought 15,000 shares at $1.89 per share. Following this transaction, he directly holds 397,500 common shares.
His holdings include 62,500 unvested restricted stock units granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock and vests in four equal annual installments starting January 2, 2027.
Compass Therapeutics General Counsel Jonathan Anderman purchased 25,000 shares of common stock in an open-market transaction at $1.89 per share. After this buy, he directly holds 196,000 shares. 150,000 of these shares are unvested restricted stock units granted on January 2, 2026, which vest in four equal annual installments starting January 2, 2027, subject to service-based vesting conditions.
Compass Therapeutics, Inc. reported that its General Counsel, Jonathan Anderman, received a grant of 25,000 shares of common stock at an award value of $1.89 per share as equity compensation. Following this grant, he holds 196,000 shares in total.
The filing notes that 150,000 of these shares are unvested restricted stock units granted on January 2, 2026. Each RSU converts into one share of common stock if service-based vesting conditions are met, vesting in four equal annual installments starting January 2, 2027.
Lerner Neil reported acquisition or exercise transactions in this Form 4 filing.
Compass Therapeutics, Inc. Chief Accounting Officer Neil Lerner received a grant of 15,000 shares of common stock at $1.89 per share on April 29, 2026, increasing his direct holdings to 397,500 shares. A footnote notes that 62,500 of these shares are unvested restricted stock units granted on January 2, 2026, which vest in four equal annual installments starting January 2, 2027 under service-based conditions.
Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported a Form 4 transaction involving company common stock. On 02/08/2026, 36,687 shares of common stock were withheld by the issuer at $6.52 per share to cover tax withholding obligations tied to vesting restricted stock units.
After this tax withholding, Schuetz beneficially owns 6,603,336 shares of common stock. This includes unvested RSUs: 125,000 shares from a February 8, 2023 grant vesting in four equal annual installments starting February 8, 2024; 318,750 shares from a January 9, 2024 grant vesting annually starting January 9, 2025; and 250,000 shares from a January 2, 2026 grant vesting annually starting January 2, 2027.
Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported an automatic share withholding related to equity compensation. On January 9, 2026, 46,777 shares of common stock were withheld by the company at $5.35 per share to cover tax obligations arising from the vesting of restricted stock units. After this tax withholding, Schuetz beneficially owned 6,640,023 shares of common stock.
The filing also notes unvested restricted stock units: 250,000 RSUs from a February 8, 2023 grant, 318,750 RSUs from a January 9, 2024 grant, and 250,000 RSUs from a January 2, 2026 grant. Each award vests in four equal annual installments, with first vesting dates in 2024, 2025, and 2027, respectively.
Compass Therapeutics, Inc. (CMPX) reported an insider ownership update for Chief Executive Officer and Director Thomas J. Schuetz. On 11/16/2025, 44,025 shares of common stock were withheld at a price of $4.83 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this tax withholding transaction, Schuetz beneficially owns 6,436,800 shares of Compass Therapeutics common stock.
The filing notes that 250,000 of these shares relate to unvested RSUs granted on February 8, 2023, which vest in four equal annual installments starting on February 8, 2024. An additional 478,125 shares relate to unvested RSUs granted on January 9, 2024, also vesting in four equal annual installments beginning on January 9, 2025. Each RSU represents a contingent right to receive one share of common stock, subject to continued service-based vesting conditions.